実臨床におけるレジパスビル/ソホスブビル又はシメプレビル/ペグインターフェロン/リバビリン服用中のC型慢性肝炎患者のQOL評価

• 四十物 由香

  昭和大学薬学部臨床薬学講座薬物治療学部門 株式会社日立製作所日立総合病院薬務局

• 神山 紀子

  昭和大学薬学部臨床薬学講座薬物治療学部門

• 鴨志田 敏郎

  株式会社日立製作所日立総合病院消化器内科

• 山元 俊憲

  公益財団法人昭和大学医学・医療振興財団

• 向後 麻里

  昭和大学薬学部臨床薬学講座薬物治療学部門

書誌事項

タイトル別名

• QOL Assessment in Chronic Hepatitis C Patients Receiving Ledipasvir/ Sofosbuvir or Simeprevir/Peginterferon/Ribavirin in Clinical Practice
• ジツ リンショウ ニ オケル レジパスビル/ソホスブビル マタ ワ シメプレビル/ペグインターフェロン/リバビリン フクヨウ チュウ ノ Cガタ マンセイ カンエン カンジャ ノ QOL ヒョウカ

抄録

Recently, a clinical study using a Chronic Liver Disease Questionnaire (CLDQ) showed that ledipasvir/sofosbuvir (LDV/SOF)-treated patients' QOL was more favorable than that of IFN/ribavirin (RBV)-treated patients. However, no study has reported QOL assessment in clinical practice. In this study, we compared the QOL between patients treated with LDV/SOF and those treated with simeprevir (SMV)/peginterferon (Peg-IFN)/RBV to provide QOL information in clinical practice. The subjects were 169 patients with type I chronic hepatitis C or compensated cirrhosis C (Child-Pugh Grade A) who were treated with SMV/Peg-IFN/RBV or LDV/SOF in Hitachi General Hospital. The QOL was assessed ≥2 weeks after the start of administration using the Japanese version of the CLDQ (Kida et al., 2008 version). The total CLDQ score in the LDV/SOF group was significantly higher than in the SMV/Peg-IFN/RBV group (6.59 vs. 6.38, respectively, p=0.007). In particular, the scores for 4 domains (abdominal symptoms, systemic symptoms, activity, and emotional function) in the former were significantly higher than in the latter (p<0.05). Furthermore, the rates of patients scoring 7 (no symptom) on 8 items in the former were significantly higher than in the latter (p<0.05). In clinical practice, LDV/SOF-treated patients' QOL was more favorable than that of those receiving conventional treatment with IFN and RBV. This study may make it possible for health care professionals to provide clinical QOL information on LDV/SOF therapy to patients. Furthermore, QOL information may promote decision-making for treatment, leading to effective treatment.

収録刊行物

• 薬学雑誌

  薬学雑誌 139 (11), 1427-1434, 2019-11-01

  公益社団法人 日本薬学会

キーワード

• ledipasvir/sofosbuvir
• Chronic Liver Disease Questionnaire
• chronic hepatitis C

詳細情報

• CRID: 1390001277380647040
• NII論文ID: 130007740034
• NII書誌ID: AN00284903
• DOI: 10.1248/yakushi.19-00019
• ISSN: 13475231
• ISSN: 00316903
• NDL書誌ID: 030080412
• PubMed: 31685739
• Web Site: https://ndlsearch.ndl.go.jp/books/R000000004-I030080412
• Web Site: https://www.jstage.jst.go.jp/article/yakushi/139/11/139_19-00019/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/2020055162
• 本文言語コード: ja
• データソース種別:
  • JaLC
  • NDL
  • Crossref
  • PubMed
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可